当前位置： SCI文献检索 > ACS Infectious Diseases期刊下所有文献 > Efforts Aimed To Reduce Attrition in Antimalarial Drug Discovery: A Systematic Evaluation of the Current Antimalarial Targets Portfolio.

Efforts Aimed To Reduce Attrition in Antimalarial Drug Discovery: A Systematic Evaluation of the Current Antimalarial Targets Portfolio.

Abstract：

:Malaria remains a major global health problem. In 2015 alone, more than 200 million cases of malaria were reported, and more than 400,000 deaths occurred. Since 2010, emerging resistance to current front-line ACTs (artemisinin combination therapies) has been detected in endemic countries. Therefore, there is an urgency for new therapies based on novel modes of action, able to relieve symptoms as fast as the artemisinins and/or block malaria transmission. During the past few years, the antimalarial community has focused their efforts on phenotypic screening as a pragmatic approach to identify new hits. Optimization efforts on several chemical series have been successful, and clinical candidates have been identified. In addition, recent advances in genetics and proteomics have led to the target deconvolution of phenotypic clinical candidates. New mechanisms of action will also be critical to overcome resistance and reduce attrition. Therefore, a complementary strategy focused on identifying well-validated targets to start hit identification programs is essential to reinforce the clinical pipeline. Leveraging published data, we have assessed the status quo of the current antimalarial target portfolio with a focus on the blood stage clinical disease. From an extensive list of reported Plasmodium targets, we have defined triage criteria. These criteria consider genetic, pharmacological, and chemical validation, as well as tractability/doability, and safety implications. These criteria have provided a quantitative score that has led us to prioritize those targets with the highest probability to deliver successful and differentiated new drugs.

journal_name

ACS Infect Dis

journal_title

ACS infectious diseases

authors

Chaparro MJ,Calderón F,Castañeda P,Fernández-Alvaro E,Gabarró R,Gamo FJ,Gómez-Lorenzo MG,Martín J,Fernández E

doi

10.1021/acsinfecdis.7b00211

subject

Has Abstract

pub_date

2018-04-13 00:00:00

pages

568-576

issue

4

issn

2373-8227

journal_volume

4

pub_type

杂志文章

相关文献

ACS Infectious Diseases文献大全
  • Rapid in Vitro Assessment of Clostridioides difficile Inhibition by Probiotics Using Dielectrophoresis to Quantify Cell Structure Alterations.

    abstract：:Clostridioides difficile (C. difficile) infection (CDI) is the primary cause of nosocomial antibiotic-associated diarrhea, with high recurrence rates following initial antibiotic treatment regimens. Restoration of the host gut microbiome through probiotic therapy is under investigation to reduce recurrence. Current in...

    journal_title：ACS infectious diseases

    pub_type： 杂志文章

    doi：10.1021/acsinfecdis.9b00415

    authors： Moore JH,Honrado C,Stagnaro V,Kolling G,Warren CA,Swami NS

    更新日期：2020-05-08 00:00:00

  • Ten Years with New Delhi Metallo-β-lactamase-1 (NDM-1): From Structural Insights to Inhibitor Design.

    abstract：:The worldwide emergence of New Delhi metallo-β-lactamase-1 (NDM-1) as a carbapenemase able to hydrolyze nearly all available β-lactam antibiotics has characterized the past decade, endangering efficacious antibacterial treatments. No inhibitors for NDM-1 are available in therapy, nor are promising compounds in the pip...

    journal_title：ACS infectious diseases

    pub_type： 杂志文章,评审

    doi：10.1021/acsinfecdis.8b00247

    authors： Linciano P,Cendron L,Gianquinto E,Spyrakis F,Tondi D

    更新日期：2019-01-11 00:00:00

  • Two-Way Regulation of MmpL3 Expression Identifies and Validates Inhibitors of MmpL3 Function in Mycobacterium tuberculosis.

    abstract：:MmpL3, an essential mycolate transporter in the inner membrane of Mycobacterium tuberculosis (Mtb), has been identified as a target of multiple, chemically diverse antitubercular drugs. However, several of these molecules seem to have secondary targets and inhibit bacterial growth by more than one mechanism. Here, we ...

    journal_title：ACS infectious diseases

    pub_type： 杂志文章

    doi：10.1021/acsinfecdis.0c00675

    authors： Grover S,Engelhart CA,Pérez-Herrán E,Li W,Abrahams KA,Papavinasasundaram K,Bean JM,Sassetti CM,Mendoza-Losana A,Besra GS,Jackson M,Schnappinger D

    更新日期：2021-01-08 00:00:00

  • Mechanistic Evaluation of Lipopolysaccharide-Alexidine Interaction Using Spectroscopic and in Silico Approaches.

    abstract：:The increasing problem of multidrug resistance (MDR) in bacteria calls for discovery of new molecules and diagnostic methodologies that are effective against a wide range of microbial pathogens. We have studied the role of alexidine dihydrochloride (alex) as a bioaffinity ligand against lipopolysaccharide (LPS), a pat...

    journal_title：ACS infectious diseases

    pub_type： 杂志文章

    doi：10.1021/acsinfecdis.8b00087

    authors： Jagtap P,Mishra R,Khanna S,Kumari P,Mittal B,Kashyap HK,Gupta S

    更新日期：2018-11-09 00:00:00

  • Probing the Interaction of Aspergillomarasmine A with Metallo-β-lactamases NDM-1, VIM-2, and IMP-7.

    abstract：:Metallo-β-lactamases (MBLs) are a growing threat to the continued efficacy of β-lactam antibiotics. Recently, aspergillomarasmine A (AMA) was identified as an MBL inhibitor, but the mode of inhibition was not fully characterized. Equilibrium dialysis and metal analysis studies revealed that 2 equiv of AMA effectively ...

    journal_title：ACS infectious diseases

    pub_type： 杂志文章

    doi：10.1021/acsinfecdis.7b00106

    authors： Bergstrom A,Katko A,Adkins Z,Hill J,Cheng Z,Burnett M,Yang H,Aitha M,Mehaffey MR,Brodbelt JS,Tehrani KHME,Martin NI,Bonomo RA,Page RC,Tierney DL,Fast W,Wright GD,Crowder MW

    更新日期：2018-02-09 00:00:00

  • Violacein Targets the Cytoplasmic Membrane of Bacteria.

    abstract：:Violacein is a tryptophan-derived purple pigment produced by environmental bacteria, which displays multiple biological activities, including strong inhibition of Gram-positive pathogens. Here, we applied a combination of experimental approaches to identify the mechanism by which violacein kills Gram-positive bacteria...

    journal_title：ACS infectious diseases

    pub_type： 杂志文章

    doi：10.1021/acsinfecdis.8b00245

    authors： Cauz ACG,Carretero GPB,Saraiva GKV,Park P,Mortara L,Cuccovia IM,Brocchi M,Gueiros-Filho FJ

    更新日期：2019-04-12 00:00:00

  • Identification of Trypanosoma brucei AdoMetDC Inhibitors Using a High-Throughput Mass Spectrometry-Based Assay.

    abstract：:Human African trypanosomiasis (HAT) is a fatal infectious disease caused by the eukaryotic pathogen Trypanosoma brucei (Tb). Available treatments are difficult to administer and have significant safety issues. S-Adenosylmethionine decarboxylase (AdoMetDC) is an essential enzyme in the parasite polyamine biosynthetic p...

    journal_title：ACS infectious diseases

    pub_type： 杂志文章

    doi：10.1021/acsinfecdis.7b00022

    authors： Volkov OA,Cosner CC,Brockway AJ,Kramer M,Booker M,Zhong S,Ketcherside A,Wei S,Longgood J,McCoy M,Richardson TE,Wring SA,Peel M,Klinger JD,Posner BA,De Brabander JK,Phillips MA

    更新日期：2017-07-14 00:00:00

  • Alternative Pathway to a Glycopeptide-Resistant Cell Wall in the Balhimycin Producer Amycolatopsis balhimycina.

    abstract：:Balhimycin, a vancomycin-type glycopeptide, is a lipid II targeting antibiotic produced by Amycolatopsis balhimycina. A. balhimycina has developed a self-resistance mechanism based on the synergistic action of different enzymes resulting in modified peptidoglycan. The canonical resistance mechanism against glycopeptid...

    journal_title：ACS infectious diseases

    pub_type： 杂志文章

    doi：10.1021/acsinfecdis.5b00011

    authors： Frasch HJ,Kalan L,Kilian R,Martin T,Wright GD,Stegmann E

    更新日期：2015-06-12 00:00:00

  • N-Myristoylation as a Drug Target in Malaria: Exploring the Role of N-Myristoyltransferase Substrates in the Inhibitor Mode of Action.

    abstract：:Malaria continues to be a significant cause of death and morbidity worldwide, and there is a need for new antimalarial drugs with novel targets. We have focused as a potential target for drug development on N-myristoyl transferase (NMT), an enzyme that acylates a wide range of substrate proteins. The NMT substrates in...

    journal_title：ACS infectious diseases

    pub_type： 杂志文章,评审

    doi：10.1021/acsinfecdis.7b00203

    authors： Schlott AC,Holder AA,Tate EW

    更新日期：2018-04-13 00:00:00

  • Getting Drugs through Small Pores: Exploiting the Porins Pathway in Pseudomonas aeruginosa.

    abstract：:Understanding molecular properties of outer membrane channels of Gram-negative bacteria is of fundamental significance as they are the entry point of polar antibiotics into bacteria. Outer membrane proteomics revealed OccK8 (OprE) to be among the five most expressed substrate specific channels of the clinically import...

    journal_title：ACS infectious diseases

    pub_type： 杂志文章

    doi：10.1021/acsinfecdis.8b00149

    authors： Samanta S,Bodrenko I,Acosta-Gutiérrez S,D'Agostino T,Pathania M,Ghai I,Schleberger C,Bumann D,Wagner R,Winterhalter M,van den Berg B,Ceccarelli M

    更新日期：2018-10-12 00:00:00

  • Introduction of a Thio Functional Group to Diazabicyclooctane: An Effective Modification to Potentiate the Activity of β-Lactams against Gram-Negative Bacteria Producing Class A, C, and D Serine β-Lactamases.

    abstract：:By the emergence and worldwide spread of multi-drug-resistant Gram-negative bacteria, there have been growing demands for efficacious drugs to cure these resistant infections. The key mechanism for resistance to β-lactam antibiotics is the production of β-lactamases, which hydrolyze and deactivate β-lactams. Diazabicy...

    journal_title：ACS infectious diseases

    pub_type： 杂志文章

    doi：10.1021/acsinfecdis.0c00560

    authors： Fujiu M,Yokoo K,Sato J,Shibuya S,Komano K,Kusano H,Sato S,Aoki T,Kohira N,Miyagawa S,Kawachi T,Yamawaki K

    更新日期：2020-11-13 00:00:00

  • Modification at the 2'-Position of the 4,5-Series of 2-Deoxystreptamine Aminoglycoside Antibiotics To Resist Aminoglycoside Modifying Enzymes and Increase Ribosomal Target Selectivity.

    abstract：:A series of derivatives of the 4,5-disubstituted class of 2-deoxystreptamine aminoglycoside antibiotics neomycin, paromomycin, and ribostamycin was prepared and assayed for (i) their ability to inhibit protein synthesis by bacterial ribosomes and by engineered bacterial ribosomes carrying eukaryotic decoding A sites, ...

    journal_title：ACS infectious diseases

    pub_type： 杂志文章

    doi：10.1021/acsinfecdis.9b00128

    authors： Sati GC,Sarpe VA,Furukawa T,Mondal S,Mantovani M,Hobbie SN,Vasella A,Böttger EC,Crich D

    更新日期：2019-10-11 00:00:00

  • Antisense Inhibitors Retain Activity in Pulmonary Models of Burkholderia Infection.

    abstract：:The Burkholderia cepacia complex is a group of Gram-negative bacteria that are opportunistic pathogens in immunocompromised individuals, such as those with cystic fibrosis (CF) or chronic granulomatous disease (CGD). Burkholderia are intrinsically resistant to many antibiotics and the lack of antibiotic development ne...

    journal_title：ACS infectious diseases

    pub_type： 杂志文章

    doi：10.1021/acsinfecdis.7b00235

    authors： Daly SM,Sturge CR,Marshall-Batty KR,Felder-Scott CF,Jain R,Geller BL,Greenberg DE

    更新日期：2018-05-11 00:00:00

  • Overcoming an Extremely Drug Resistant (XDR) Pathogen: Avibactam Restores Susceptibility to Ceftazidime for Burkholderia cepacia Complex Isolates from Cystic Fibrosis Patients.

    abstract：:Burkholderia multivorans is a significant health threat to persons with cystic fibrosis (CF). Infections are difficult to treat as this pathogen is inherently resistant to multiple antibiotics. Susceptibility testing of isolates obtained from CF respiratory cultures revealed that single agents selected from different ...

    journal_title：ACS infectious diseases

    pub_type： 杂志文章

    doi：10.1021/acsinfecdis.7b00020

    authors： Papp-Wallace KM,Becka SA,Zeiser ET,Ohuchi N,Mojica MF,Gatta JA,Falleni M,Tosi D,Borghi E,Winkler ML,Wilson BM,LiPuma JJ,Nukaga M,Bonomo RA

    更新日期：2017-07-14 00:00:00

  • 1,2,3-Triazolylmethaneboronate: A Structure Activity Relationship Study of a Class of β-Lactamase Inhibitors against Acinetobacter baumannii Cephalosporinase.

    abstract：:Boronic acid transition state inhibitors (BATSIs) are known reversible covalent inhibitors of serine β-lactamases. The selectivity and high potency of specific BATSIs bearing an amide side chain mimicking the β-lactam's amide side chain are an established and recognized synthetic strategy. Herein, we describe a new cl...

    journal_title：ACS infectious diseases

    pub_type： 杂志文章

    doi：10.1021/acsinfecdis.0c00254

    authors： Caselli E,Fini F,Introvigne ML,Stucchi M,Taracila MA,Fish ER,Smolen KA,Rather PN,Powers RA,Wallar BJ,Bonomo RA,Prati F

    更新日期：2020-07-10 00:00:00

  • The Bare Essentials of Antibiotic Target Validation.

    abstract：:The convergence of competitive fitness experiments and phenotypic screening would seem to be an auspicious beginning for validation of an antibacterial target. IMPDH was already identified an essential protein in Mycobacterium tuberculosis when not one, but two, groups discovered inhibitors with promising antitubercul...

    journal_title：ACS infectious diseases

    pub_type： 杂志文章

    doi：10.1021/acsinfecdis.6b00185

    authors： Hedstrom L

    更新日期：2017-01-13 00:00:00

  • Global Profiling and Inhibition of Protein Lipidation in Vector and Host Stages of the Sleeping Sickness Parasite Trypanosoma brucei.

    abstract：:The enzyme N-myristoyltransferase (NMT) catalyzes the essential fatty acylation of substrate proteins with myristic acid in eukaryotes and is a validated drug target in the parasite Trypanosoma brucei, the causative agent of African trypanosomiasis (sleeping sickness). N-Myristoylation typically mediates membrane loca...

    journal_title：ACS infectious diseases

    pub_type： 杂志文章

    doi：10.1021/acsinfecdis.6b00034

    authors： Wright MH,Paape D,Price HP,Smith DF,Tate EW

    更新日期：2016-06-10 00:00:00

  • Interaction of a Model Peptide on Gram Negative and Gram Positive Bacterial Sliding Clamps.

    abstract：:Bacterial sliding clamps control the access of DNA polymerases to the replication fork and are appealing targets for antibacterial drug development. It is therefore essential to decipher the polymerase-clamp binding mode across various bacterial species. Here, two residues of the E. coli clamp binding pocket, EcS346 a...

    journal_title：ACS infectious diseases

    pub_type： 杂志文章

    doi：10.1021/acsinfecdis.9b00089

    authors： André C,Martiel I,Wolff P,Landolfo M,Lorber B,Silva da Veiga C,Dejaegere A,Dumas P,Guichard G,Oliéric V,Wagner J,Burnouf DY

    更新日期：2019-06-14 00:00:00

  • Toward Curative Immunomodulation Strategies for Chronic Hepatitis B Virus Infection.

    abstract：:Chronic hepatitis B virus (HBV) infection remains a major cause of morbidity and mortality worldwide. HBV surface antigen loss is considered a functional cure and is an ideal goal for antiviral therapy. However, current treatment regimens, including nucleos(t)ide analogues or interferons monotherapy and combination th...

    journal_title：ACS infectious diseases

    pub_type： 杂志文章,评审

    doi：10.1021/acsinfecdis.8b00297

    authors： Zhu W,Liu H,Zhang X

    更新日期：2019-05-10 00:00:00

  • Systematic Analysis of Structure Similarity between Zika Virus and Other Flaviviruses.

    abstract：:Zika virus (ZIKV) infection has caused global concern because of its association with fetal microcephaly and serious neurological complications in adults since 2016. Currently, no specific anti-ZIKV therapy is available to control ZIKV infection. During the last couple of years, the intensive investigation of ZIKV str...

    journal_title：ACS infectious diseases

    pub_type： 杂志文章,评审

    doi：10.1021/acsinfecdis.9b00047

    authors： Hu Y,Sun L

    更新日期：2019-07-12 00:00:00

  • Diaza-anthracene Antibiotics from a Freshwater-Derived Actinomycete with Selective Antibacterial Activity toward Mycobacterium tuberculosis.

    abstract：:Multidrug- and extensively drug-resistant strains of Mycobacterium tuberculosis are resistant to first- and second-line drug regimens and resulted in 210,000 fatalities in 2013. In the current study, we screened a library of aquatic bacterial natural product fractions for their ability to inhibit this pathogen. A frac...

    journal_title：ACS infectious diseases

    pub_type： 杂志文章

    doi：10.1021/acsinfecdis.5b00005

    authors： Mullowney MW,Hwang CH,Newsome AG,Wei X,Tanouye U,Wan B,Carlson S,Barranis NJ,hAinmhire E,Chen WL,Krishnamoorthy K,White J,Blair R,Lee H,Burdette JE,Rathod PK,Parish T,Cho S,Franzblau SG,Murphy BT

    更新日期：2015-04-10 00:00:00

  • Zika Virus: Diagnosis, Therapeutics, and Vaccine.

    abstract：:The current explosive epidemic of Zika virus in South and Central America, as well as the Caribbean, poses a global public health emergency. Here we comment on the challenges on development of better diagnosis and potential therapeutics and vaccine for Zika virus. ...

    journal_title：ACS infectious diseases

    pub_type： 杂志文章

    doi：10.1021/acsinfecdis.6b00030

    authors： Shan C,Xie X,Barrett AD,Garcia-Blanco MA,Tesh RB,Vasconcelos PF,Vasilakis N,Weaver SC,Shi PY

    更新日期：2016-03-11 00:00:00

  • Inhibition of Biofilm Formation by Candida albicans and Polymicrobial Microorganisms by Nepodin via Hyphal-Growth Suppression.

    abstract：:Candida albicans is an opportunistic pathogenic yeast and is responsible for candidiasis. It readily colonizes host tissues and implant devices, and forms biofilms, which play an important role in pathogenesis and drug resistance. In this study, the antibiofilm, antihyphal, and antivirulence activities of nepodin, iso...

    journal_title：ACS infectious diseases

    pub_type： 杂志文章

    doi：10.1021/acsinfecdis.9b00033

    authors： Lee JH,Kim YG,Khadke SK,Yamano A,Watanabe A,Lee J

    更新日期：2019-07-12 00:00:00

  • An "Unlikely" Pair: The Antimicrobial Synergy of Polymyxin B in Combination with the Cystic Fibrosis Transmembrane Conductance Regulator Drugs KALYDECO and ORKAMBI.

    abstract：:Novel combination therapies are desperately needed for combating lung infections caused by bacterial "superbugs". This study aimed to investigate the synergistic antibacterial activity of polymyxin B in combination with the cystic fibrosis (CF) drugs KALYDECO (ivacaftor) and ORKAMBI (ivacaftor + lumacaftor) against Gr...

    journal_title：ACS infectious diseases

    pub_type： 杂志文章

    doi：10.1021/acsinfecdis.6b00035

    authors： Schneider EK,Azad MA,Han ML,Tony Zhou Q,Wang J,Huang JX,Cooper MA,Doi Y,Baker MA,Bergen PJ,Muller MT,Li J,Velkov T

    更新日期：2016-07-08 00:00:00

  • Photodynamic Inactivation of ESKAPE Group Bacterial Pathogens in Planktonic and Biofilm Cultures Using Metallated Porphyrin-Doped Conjugated Polymer Nanoparticles.

    abstract：:Photodynamic inactivation (PDI) protocols using photoactive metallated porphyrin-doped conjugated polymer nanoparticles (CPNs) and blue light were developed to eliminate multidrug-resistant pathogens. CPNs-PDI protocols using varying particle concentrations and irradiation doses were tested against nine pathogenic bac...

    journal_title：ACS infectious diseases

    pub_type： 杂志文章

    doi：10.1021/acsinfecdis.0c00268

    authors： Martínez SR,Ibarra LE,Ponzio RA,Forcone MV,Wendel AB,Chesta CA,Spesia MB,Palacios RE

    更新日期：2020-08-14 00:00:00

  • Virus-like Particle Display of the α-Gal Epitope for the Diagnostic Assessment of Chagas Disease.

    abstract：:The α-Gal antigen [Galα(1,3)Galβ(1,4)GlcNAcα] is an immunodominant epitope displayed by infective trypomastigote forms of Trypanosoma cruzi, the causative agent of Chagas disease. A virus-like particle displaying a high density of α-Gal was found to be a superior reagent for the ELISA-based serological diagnosis of Ch...

    journal_title：ACS infectious diseases

    pub_type： 杂志文章

    doi：10.1021/acsinfecdis.6b00114

    authors： Brito CR,McKay CS,Azevedo MA,Santos LC,Venuto AP,Nunes DF,D'Ávila DA,Rodrigues da Cunha GM,Almeida IC,Gazzinelli RT,Galvão LM,Chiari E,Sanhueza CA,Finn MG,Marques AF

    更新日期：2016-12-09 00:00:00

  • Fitness Landscape of the Immune Compromised Favors the Emergence of Antibiotic Resistance.

    abstract：:Antibiotic resistance can come at a high cost, both in terms of fitness for the pathogen and poorer outcomes for patients. The fitness landscape encountered by bacterial pathogens varies greatly throughout patient populations in terms of host immunity as well as the duration and spectrum of antibiotics encountered. Se...

    journal_title：ACS infectious diseases

    pub_type： 杂志文章

    doi：10.1021/acsinfecdis.8b00158

    authors： Margolis E,Rosch JW

    更新日期：2018-09-14 00:00:00

  • Daptomycin Leakage Is Selective.

    abstract：:Daptomycin is a lipopeptide antibiotic approved for use against Gram-positive organisms, including highly resistant species. A number of studies have suggested that daptomycin kills bacteria by membrane permeabilization and depolarization. Recently a model membrane system consisting of 1,2-dimyristoyl-sn-glycero-3-pho...

    journal_title：ACS infectious diseases

    pub_type： 杂志文章

    doi：10.1021/acsinfecdis.6b00152

    authors： Zhang J,Scoten K,Straus SK

    更新日期：2016-10-14 00:00:00

  • Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential.

    abstract：:The recent outbreak of coronavirus disease 2019 (COVID-19) highlights an urgent need for therapeutics. Through a series of drug repurposing screening campaigns, niclosamide, an FDA-approved anthelminthic drug, was found to be effective against various viral infections with nanomolar to micromolar potency such as SARS-...

    journal_title：ACS infectious diseases

    pub_type： 杂志文章,评审

    doi：10.1021/acsinfecdis.0c00052

    authors： Xu J,Shi PY,Li H,Zhou J

    更新日期：2020-05-08 00:00:00

  • Developments in Glycopeptide Antibiotics.

    abstract：:Glycopeptide antibiotics (GPAs) are a key weapon in the fight against drug resistant bacteria, with vancomycin still a mainstream therapy against serious Gram-positive infections more than 50 years after it was first introduced. New, more potent semisynthetic derivatives that have entered the clinic, such as dalbavanc...

    journal_title：ACS infectious diseases

    pub_type： 杂志文章

    doi：10.1021/acsinfecdis.7b00258

    authors： Blaskovich MAT,Hansford KA,Butler MS,Jia Z,Mark AE,Cooper MA

    更新日期：2018-05-11 00:00:00